Business Wire

Global Life Sciences Survey Reveals Significant Improvements in Inspection Readiness Among CROs


Veeva Systems (NYSE:VEEV) today unveiled the results of the Veeva 2016 Paperless TMF Survey: CRO Report. The global industry survey of trial master file (TMF) owners shows growing use of electronic trial master file (eTMF) solutions among clinical research organizations (CROs) as a result of benefits in audit and inspection readiness. In addition, findings reveal that CROs are leading the drive toward active TMF management and making strides in the use of performance metrics and data to improve the efficiency and speed of clinical trials.

eTMF Solutions Significantly Improve Inspection Readiness

eTMFs are helping CROs to maintain complete and accessible trial master files to reduce the number of inspection findings. CROs who use eTMF applications are achieving significant improvements across major inspection finding categories such as fewer duplicate documents (61%), misfiled documents (53%), and incomplete documents (51%).

Given these benefits, one of the top drivers of eTMF adoption among a majority of CROs (65%) is improved audit and inspection readiness. At the same time, CROs are now less reliant on document exchange methods that are more difficult to track and provide little to no audit trail. For example, the use of email for document exchange is down significantly from 80% in 2014 to 61% today, while almost a third (31%) are using an eTMF application to share TMF documents with sponsors (up from 24% in 2014).

CROs Leading Transition to Active TMF Management

With a focus on improving inspection readiness, CROs are shifting to an active TMF management approach, a trend that has increased since the first Veeva Paperless TMF Survey in 2014. In active TMF management, purpose-built eTMF applications manage documents and processes in real-time as the TMF is being generated and provide global access for stakeholders. Conversely, in passive TMF management, TMF documents are simply stored and archived in file systems and other static repositories at the end of a trial rather than as part of the trial workflow.

Nearly one-third of CROs (30%) now use purpose-built eTMF applications that enable active TMF management, up from 21% in 2014. At the same time, there was a significant drop in the use of passive eTMF systems, including cloud file shares (9% in 2016 vs. 21% in 2014) and local file systems (16% in 2016 vs. 26% in 2014). In addition, CROs have significantly reduced the amount of TMF documents managed on paper, with less than a quarter (22%) reporting that most to all TMF documents are managed on paper (down from 47% in 2014).

eTMFs Provide Better Visibility into TMF Performance

Another key driver of eTMF adoption among a majority of CROs (57%) is improved visibility into performance metrics. CROs are not only capturing metrics but also making large strides in putting the data to use, with a quarter of CROs (24%) now extensively using TMF data to improve trial processes (up from 16% in 2015) and another 46% leveraging data in some cases (up from 40% in 2015).

In terms of other key benefits of eTMF adoption, 44% of CROs find that they have better visibility into performance metrics. In addition, a majority of CROs have achieved significant improvements in central and remote auditing (56%) and automated tracking and reporting of documents (56%), both of which are key in providing timely and accurate status updates to sponsors.

“Over the past several years CROs have played a pivotal role in moving the life sciences industry toward more efficient clinical trial processes,” said Jill Johnston, vice president of Veeva Vault Clinical. “As clinical trials become increasingly outsourced, we’ll see that trend continue especially as demand grows for unifying systems, processes, and stakeholders across clinical operations.”

To hear the full results of the Veeva 2016 Paperless TMF Survey: CRO Report, see Veeva’s presentation at the Outsourcing in Clinical Trials New England conference on September 7 at 3:15 p.m. Conference attendees can also visit Veeva booth #7 for a copy or download it here.

Survey Methods

The Veeva 2016 Paperless TMF Survey: CRO Report consisted of 13 questions, many of which included sub-questions with response matrices. Survey questions were designed for individuals with knowledge of TMF document processes and with partial or full responsibility for a TMF within their organization. The survey was commissioned by Veeva Systems and conducted by Fierce Markets. Completion of the survey was voluntary, and a $5 donation was made to Doctors Without Borders for each valid completion of the full survey. All respondents were offered a summary of the survey results. No other compensation was offered or provided.

Additional Information

For more on Veeva Vault eTMF, please visit:

Stay updated on the latest Veeva news on LinkedIn:

Follow @Veeva_EU on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 450 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices in Europe, Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the company’s filing on Form 10-Q for the period ended April 30, 2016. This is available on the company’s website at under the Investors section and on the SEC’s website at Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.


Contact information

Veeva Systems Inc.
Sue Glanville
+44 (0) 7715 817589
Cate Bonthuys
+44 (0) 7746 546773

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on